What Cemcat does

Cemcat (Centre d'Esclerosi Múltiple de Catalunya), legally structured as FUNDACIÓ PRIVADA CEMCAT, is a Barcelona-based private non-profit foundation operating as a flagship reference center for multiple sclerosis (MS) and other degenerative diseases of the nervous system. The center is physically embedded within the Vall d'Hebron Barcelona Hospital Campus and delivers an integrated three-pillar model: (1) clinical patient care for MS patients referred through the Catalan Institute of Health public healthcare system, (2) clinical and translational research through the Clinical Neuroimmunology group at VHIR, and (3) postgraduate education and training for healthcare professionals.

The organization's core products span patient services, clinical trials (including contributions to landmark studies such as the ORATORIO phase III trial for Ocrelizumab in primary progressive MS, published in the New England Journal of Medicine), a 60 ECTS Online Master in Neuroimmunology delivered through the iNeuroCampus platform in partnership with the Autonomous University of Barcelona (now in its 19th edition), observerships and fellowship placements (70-80 professionals annually, nearly 60% international), and a doctoral theses program that has produced over 20 completed theses since 2014. Its underlying technology is biomedical and clinical rather than software-based, with no proprietary AI/ML systems, APIs, or SDKs disclosed.

Cemcat's revenue model is mixed: clinical services are reimbursed through the Catalan public healthcare system; research is funded by competitive Catalan, Spanish (Carlos III Health Institute), and European Union grants, with a cumulative ~€10M raised between 2008 and 2021; and the Master's program generates tuition at €3,960 per student. The organization is led by Dr. Xavier Montalban (Director, Charcot Award 2023 recipient, ECTRIMS 2016 President) and Dr. Mar Tintoré (Head of Care), with a multidisciplinary team of 51-100 employees including neurologists, nurses, physiotherapists, occupational therapists, and speech therapists.

Name

Cemcat

Legal name

FUNDACIÓ PRIVADA CEMCAT

Website

https://cem-cat.org

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Cemcat is a Barcelona-based specialized medical center providing multiple sclerosis patient care, clinical research, and postgraduate neuroimmunology education as part of the Vall d'Hebron Barcelona Hospital Campus. It serves MS patients, neurologists, and international medical trainees under Dr. Xavier Montalban's leadership.

Ownership category

akta.pro rank

Product category

Specialized Multiple Sclerosis Medical Center

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231), Medical and Diagnostic Laboratories (6215), Colleges, Universities, and Professional Schools (6113)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Neurologic Rehabilitation Centers (Stroke/TBI/SCI/MS/Parkinson’s) (HLADAJAH)

akta.pro secondary industries

Clinical Research & Trial Central Laboratories (HLAFAMAL), Neurodiagnostic Centers (EEG/EMG/NCS) (HLAFAKAK)

Keywords

• Multiple sclerosis care
• Neuroimmunology research
• Clinical trials MS
• Medical postgraduate education
• Specialized neurology center

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Healthcare Services: Provides specialized medical care for multiple sclerosis patients through the public healthcare system of Catalonia
2. Educational Programs: Online Master in Neuroimmunology program offering postgraduate university training; 60 ECTS credits over 11 months; attracts healthcare professionals internationally

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

Cemcat operates as a specialized medical center for the diagnosis, treatment, and ongoing management of multiple sclerosis and related neuroimmunological diseases. It delivers integrated clinical care, leads international clinical trials and MS research, and runs postgraduate education including the Online Master in Neuroimmunology (60 ECTS) accredited by the Autonomous University of Barcelona. The center operates as a private foundation within the Vall d'Hebron Barcelona Hospital Campus.

Product overview

Cemcat offers a comprehensive portfolio of healthcare, research, and educational services centered on multiple sclerosis. The core offerings include direct patient care, clinical trials, and professional training programs. The Online Master in Neuroimmunology serves as the flagship educational product, offering 60 ECTS credits in partnership with the Autonomous University of Barcelona. Professional observerships and fellowships provide hands-on training for 70-70 professionals annually. The doctoral theses program supports advanced research with over 20 completed since 2014. These services are interconnected through Cemcat's multidisciplinary team and research infrastructure at the Vall d'Hebron Barcelona Hospital Campus.

Differentiator

Problem solved

Functional benefit

Brands

• Cemcat Chair of Neuroimmunology: Academic partnership established in 2015 between Cemcat and the Autonomous University of Barcelona (UAB) to promote high-quality teaching with scientific basis and research transfer vocation.

Products and services

• Specialized Multiple Sclerosis Patient Care (Assistència) Multidisciplinary diagnosis, treatment, and long-term management of multiple sclerosis and related neuroimmunological diseases, delivered to patients referred through the Catalan public healthcare system at the Vall d'Hebron Barcelona Hospital Campus. Combines neurology, specialized nursing, physiotherapy, occupational therapy, speech therapy, neuropsychology, and emotional support.
• Online Master in Neuroimmunology Online postgraduate master's program in neuroimmunology offered as an official degree from the Autonomous University of Barcelona (UAB), accredited with 60 ECTS credits over 11 months. Delivered in Spanish and English through 10 sections with theoretical content and practical debate forums on the iNeuroCampus platform. Priced at €3,960 per student, with up to 60 students per edition.
• Observerships and Fellowships (Estades Formatives) Hands-on training placements at Cemcat for healthcare professionals from around the world, covering different areas of multiple sclerosis and related neurological diseases. Placements range from short observerships to fellowships of one year or longer, with 70-80 professionals participating annually and nearly 60% drawn from outside Spain (primarily Europe and Latin America).
• Clinical Trials Program (Assaigs Clínics) International clinical trials and research projects led by Cemcat researchers covering diagnostic criteria revisions, vaccination strategies, treatment efficacy (e.g., Ocrelizumab in primary progressive MS in ORATORIO), and rehabilitation approaches for multiple sclerosis patients. Patients gain access to cutting-edge therapies and Cemcat researchers contribute to global MS evidence generation.
• Doctoral Theses Program Doctoral research program supervised by Cemcat researchers, covering immunology, genetics, neuroimaging, and treatment outcomes in multiple sclerosis. Over 20 doctoral theses have been presented since 2014.

Quantifiable outcome

• 66.6% of patients protected with single-dose vaccination strategy
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Five partnerships are on record, tiered core and minor.

• Autonomous University of Barcelona (UAB)coreStrategic or Co-development Partner · 1 January 2015Academic partner for the Online Master in Neuroimmunology (60 ECTS, accredited by UAB). Dr. Xavier Montalban is Associate Professor of UAB. Undergrad training at UAB Medical Faculty. Joint doctoral thesis supervision.
• Multiple Sclerosis Foundation (FEM) - Fundació Esclerosi MúltiplecoreStrategic or Co-development Partner · 1 January 2015Collaborated in establishing the Cemcat Chair of Neuroimmunology (2015). Co-development of educational programs. FEM and Genzyme supported the chair agreement. Dr. Xavier Montalban serves as Vice-President of the foundation.
• Vall d'Hebron University HospitalcoreStrategic or Co-development PartnerParent institution where Cemcat is located. Provides neurological services including the Service of Neurology. Dr. Xavier Montalban serves as Head of the Neurology Service. Located at the Vall d'Hebron Barcelona Hospital Campus.
• Vall d'Hebron Research Institute (VHIR)coreStrategic or Co-development PartnerResearch partner where Cemcat researchers conduct clinical neuroimmunology research. Dr. Montalban leads the Clinical Neuroimmunology research group. Collaborative research on MS diagnosis, treatment, and disease mechanisms.
• GenzymeminorGTM or Marketing PartnerSupported the establishment of the Cemcat Chair of Neuroimmunology in 2015 along with FEM. Biotechnology company in MS treatment space.

Scale indicators8 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Mellen Center for Multiple Sclerosis (Cleveland Clinic): Large US specialty MS centre within a major academic hospital delivering integrated care, clinical trials and research. Closely comparable to Cemcat's model of multidisciplinary MS care embedded in Vall d'Hebron, with a significantly larger patient base.
• Partners Multiple Sclerosis Center (Brigham and Women's Hospital): Harvard-affiliated specialty MS centre combining clinical care, translational research and teaching. Directly comparable to Cemcat in scope of integrated MS services, research output and academic training programmes.
• St Michael's Hospital BARLO MS Centre (Toronto): Canadian specialty MS centre integrating clinical care, imaging research and clinical trials within an academic hospital. Closely comparable structure to Cemcat's clinical-research-education model.
• Charité MS Center Berlin: European specialty MS centre combining outpatient care, clinical trials and research at a major university hospital. Directly comparable in clinical-trial activity, multilingual postgraduate training and public-hospital integration.
• Mayo Clinic — Multiple Sclerosis and Autoimmune Neurology: US-based specialty MS programme within a large multi-specialty academic medical centre, delivering integrated clinical care, research and education. A scaled-up analogue of Cemcat's integrated model.
• Corinne Goldsmith Dickinson Center for Multiple Sclerosis (Mount Sinai): Icahn School of Medicine–affiliated specialty MS centre providing integrated care, clinical trials and research training. Mirrors Cemcat's three-pillar (care, research, education) structure in a comparable academic hospital setting.
• Queen Square Multiple Sclerosis Centre (UCL Institute of Neurology): London-based specialty MS research and treatment centre within a leading European academic hospital. Comparable to Cemcat in combining clinical neurology, MRI/imaging research and trial leadership, with similarly strong international reputation.

Regional players

• Hospital Clinic de Barcelona — MS Unit: Another Barcelona-based tertiary MS clinical and research unit within a large public teaching hospital. Geographic peer that competes with Cemcat for Catalan public-system referrals and Spanish trial activity.

Others

• Multiple Sclerosis International Federation (MSIF): Global umbrella organization linking MS research and patient societies worldwide. Adjacent ecosystem participant — Cemcat collaborates with MSIF-affiliated bodies and benefits from its global advocacy and research coordination.
• ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis): Leading European scientific society for MS research and treatment, of which Cemcat's director is a past president. Provides clinical grants and congress platforms that Cemcat both benefits from and helps shape.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/cemcat_em
• Instagraminstagram.com/cemcat.em
• LinkedInlinkedin.com/company/cemcat

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cemcat